ArticleThe New England journal of medicine2022
Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply.
Article in The New England journal of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Exploring the immunological effects of antibody-drug conjugates.Nature reviews. Clinical oncology · 2026Review
- Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors.Molecular cancer therapeutics · 2026Article
- Innovative Nanocarriers of Sorafenib in the Optimisation of Therapeutic Outcome: Challenges and Applications in Breast Cancer.AAPS PharmSciTech · 2026Review
- Enhertu as an effective treatment for metastatic lung cancer with brain metastasis recurrence: a case report.Annals of medicine and surgery (2012) · 2025Article
- AI microscope facilitates accurate interpretation of HER2 immunohistochemical scores 0 and 1+ in invasive breast cancer.Scientific reports · 2025Article
- MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment.NPJ breast cancer · 2025Article
- Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Predictive and prognostic biomarkers in breast tumours.Pathology · 2024Review
- Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer.Breast cancer research and treatment · 2024Article
- Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.Virchows Archiv : an international journal of pathology · 2024Review
- Metaplastic Breast Cancer: Current Understanding and Future Directions.Clinical breast cancer · 2023Review
- Therapeutic landscape of advanced HER2-positive breast cancer in 2022.Medical oncology (Northwood, London, England) · 2022Review
- Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer.Archives of pharmacal research · 2022Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
36130006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.